Adenocarcinoma: all 1,996 studies

Page 10 of 20. Open to participants first (369), then studies with results posted, then the rest; newest registration first within each.

• Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT05528367Phase 2
• The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)CompletedNCT05524844
• FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1CompletedNCT05518071Phase 2
• Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and BorderlineCompletedNCT05514171
• Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRIStatus unknownNCT05511116
• A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT05494866Phase 1
• Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant TherapyStatus unknownNCT05489458
• A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT05484011Phase 1
• Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic AdenocarcinomaCompletedNCT05483257
• Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction CancerActive, not recruitingNCT05476796Phase 2
• A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)Status unknownNCT05466019Phase 2
• Surgical Outcome and Predictors of Overall Survival of Stage I-III Appendiceal AdenocarcinomaCompletedNCT05452382
• Precise Gene Signature for Predicting Outcomes in PDACCompletedNCT05441189
• Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT05440942Phase 1
• Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER DatabaseCompletedNCT05419349
• Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung AdenocarcinomaStatus unknownNCT05400304
• PET/MRI in Endometrial CancerWithdrawnNCT05390021Not applicable
• A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the PancreasCompletedNCT05383352Phase 1
• Fistula-associated Anal AdenocarcinomaCompletedNCT05381324
• tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancErTerminatedNCT05360264Phase 2
• Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyWithdrawnNCT05356897Phase 2
• Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric CancerStatus unknownNCT05342389Phase 2
• Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.CompletedNCT05340569Not applicable
• IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaCompletedNCT05327231Phase 1
• Methadone for 'Adenocarcinopathic' Pain TreatmentWithdrawnNCT05325164Phase 3
• A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma EsophagogastricStatus unknownNCT05315830Phase 1
• CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment RegimenActive, not recruitingNCT05312398Phase 2
• Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in MexicoCompletedNCT05305001
• CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEACompletedNCT05299476Phase 2
• Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric CancersWithdrawnNCT05296005Phase 1
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
• Klotho _ LRP-6 _ Gastric AdenocarcinomaStatus unknownNCT05293535
• Panc CA Risk Model & Biomarker Testing In High-Risk CohortWithdrawnNCT05287347
• Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic AdenocarcinomaStatus unknownNCT05275062Early Phase 1
• A Recurrence Nomogram for Hepatoid Adenocarcinoma of the StomachCompletedNCT05274464
• A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaCompletedNCT05273554Phase 1
• Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ AdenocarcinomaCompletedNCT05268510Phase 2
• Adenocarcinoma of the Uterine Cervix and HPVCompletedNCT05267834
• Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)CompletedNCT05252676
• A Real World Study of the Treatment of Gastric Adenocarcinoma With HuachansuStatus unknownNCT05249244
• Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast CancerWithdrawnNCT05244434Not applicable
• Immunohistochemical Expression of PD-L1 in Pancreatic Ductal AdenocarcinomaStatus unknownNCT05228808
• Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the LungStatus unknownNCT05228795
• A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerTerminatedNCT05226507Phase 1
• Significance of Cortactin Expression in Colorectal AdenocarcinomasCompletedNCT05225870Not applicable
• Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)CompletedNCT05216653Phase 2
• Clinical Evaluation of Detection of High Risk HPV in UrineStatus unknownNCT05210348
• THIO Sequenced With Cemiplimab in Advanced NSCLCActive, not recruitingNCT05208944Phase 2
• CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) AdenocarcinomaTerminatedNCT05207722Phase 1/2
• Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse EffectCompletedNCT05204758Phase 3
• Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ AndenocarinomaActive, not recruitingNCT05190445Phase 2
• Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung AdenocarcinomaStatus unknownNCT05185544
• Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric CancerTerminatedNCT05161572Phase 2
• A Proof-of-Concept Study Evaluating LINFU™CompletedNCT05161013Not applicable
• KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.Active, not recruitingNCT05149326Phase 3
• Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid ModelStatus unknownNCT05136014
• Combination of Capmatinib + Spartalizumab in Advanced Oesogastric AdenocarcinomaSuspendedNCT05135845Phase 2
• Long-term Outcomes After Resection of Primary Duodenal AdenocarcinomaCompletedNCT05134961
• Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus unknownNCT05111444Phase 2
• Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic AdenocarcinomaActive, not recruitingNCT05102721Phase 1/2
• A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage AdenocarcinomaSuspendedNCT05101356Phase 1/2
• Retrospective Study on the Efficacy and Tolerability of Liposomal IrinotecanStatus unknownNCT05095064
• ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung AdenocarcinomasStatus unknownNCT05079022Phase 1/2
• Intracorporeal Versus Extracorporeal Anastomosis In Laparoscopic Right Colon ResectionStatus unknownNCT05077358Not applicable
• A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid TumorsCompletedNCT05074472Phase 1/2
• Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction AdenocarcinomaWithdrawnNCT05067842
• A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic AdenocarcinomaStatus unknownNCT05066802Phase 2
• Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic CancerTerminatedNCT05065736Early Phase 1
• TheraSphere With Durvalumab and Tremelimumab for HCCActive, not recruitingNCT05063565Phase 2
• An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiation Therapy Before Surgery, SurgeryStrong StudyWithdrawnNCT05056805Not applicable
• Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric CancerStatus unknownNCT05053295Not applicable
• CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT05052567Phase 1/2
• Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal AdenocarcinomaCompletedNCT05048810Not applicable
• Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic AdenocarcinomaStatus unknownNCT05047991Phase 2
• Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic CancerStatus unknownNCT05043532Not applicable
• The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT05042128Phase 2
• A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with CancersCompletedNCT05031494Phase 2
• The Role of Systemic Immuno-inflammatory Factors in Resectable Pancreatic AdenocarcinomaCompletedNCT05025371
• Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT05024812Phase 1/2
• Peroperative Assessment of Tumour Resection Margins Using High-resolution 18F-FDG-PET/CT in Pancreatic AdenocarcinomaTerminatedNCT05023291Not applicable
• Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Phase 2
• The Diagnostic Value of Staging Laparoscopy and Computed Tomography Response Assessment in Patients With Gastric AdenocarcinomaCompletedNCT05013775
• Study of FMT Combined With Nivolumab in Gastric CancerWithdrawnNCT05001360Not applicable
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)TerminatedNCT05001282Phase 1/2
• A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT04990037Phase 1
• MFOLFIRINOX with or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic AdenocarcinomaActive, not recruitingNCT04986930Phase 2
• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic AdenocarcinomaTerminatedNCT04983407Phase 1/2
• A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric AdenocarcinomaStatus unknownNCT04977193Early Phase 1
• [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial CancerCompletedNCT04972682Not applicable
• Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric AdenocarcinomaStatus unknownNCT04948125Phase 2
• A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)TerminatedNCT04933227Phase 2
• Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid LevelsWithdrawnNCT04931420Phase 2
• Pancreatic Ductal Adenocarcinoma - Microbiome as Predictor of SubtypesStatus unknownNCT04922515Not applicable
• Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective PatientsCompletedNCT04920747
• IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment.Status unknownNCT04917263
• Real-world Data (RWD) of Ramucirumab Plus PaclitaxelStatus unknownNCT04915807
• Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal AdenocarcinomaStatus unknownNCT04915417Not applicable
• IMMUNOlogical Microenvironment in REctal Adenocarcinoma TreatmentStatus unknownNCT04915326
• Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate CancerCompletedNCT04914195Phase 3
• Surufatinib in Recurrent/Metastatic Head and Neck AdenocarcinomasStatus unknownNCT04910854Phase 2

← Adenocarcinoma overview